Standard BioTools Inc
LAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$323.89M
Close$
Share Statistics
| Market cap | $323.89 Million |
|---|---|
| Enterprise Value | $97.59 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.2 |
| Beta | 1.38 |
| Outstanding Shares | 388,202,000 |
Return
| Return on Equity | 13.94% |
|---|---|
| Return on Assets | 12.24% |
| Return on Invested Capital | -13.90% |
Valuation & Multiples
| P/E Ratio | -3.42 |
|---|---|
| PEG | 0.58 |
| Price to Sales | - |
| Price to Book Ratio | 0.79 |
| Enterprise Value to Revenue | 1.49 |
| Enterprise Value to EBIT | -1.18 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$17.80 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-0.01
Average shareholder expectationRevenue Estimate
$20.80 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.9636▲ 29.58% |
|---|---|
| Total Calls | 22,000▼ 23.88% |
| Total Puts | 21,200▲ 9.84% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 77.89%▼ 1.22% |
|---|---|
| Total Invested | $273.36M▼ 29.43% |
| Investors Holding | 156▼ 6.00% |
ESG Score
No data
About Standard BioTools Inc
627 employees
CEO: Stephen Linthwaite Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-om...